Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ · Healthcare
Ultragenyx Pharmaceutical Inc. Total Liabilities 2016–2025
Ultragenyx Pharmaceutical Inc. annual total liabilities history from 2016 to 2025. Total liabilities is the combined debt and financial obligations a company owes to creditors.
- Ultragenyx Pharmaceutical Inc. total liabilities as of December 31, 2025: 1.60B, a 29.33% increase year-over-year.
- Ultragenyx Pharmaceutical Inc. total liabilities for 2025 were 1.60B, a 29.33% increase from 2024.
- Ultragenyx Pharmaceutical Inc. total liabilities for 2024 were 1.24B, a 2.09% increase from 2023.
- Ultragenyx Pharmaceutical Inc. total liabilities for 2023 were 1.22B, a 1.90% increase from 2022.
- Ultragenyx Pharmaceutical Inc. total liabilities for 2022 were 1.19B.
Total Liabilities
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Ultragenyx Pharmaceutical Inc. Annual Total Liabilities (Millions of US $) | |
|---|---|
| 2025 | $1,605 |
| 2024 | $1,241 |
| 2023 | $1,216 |
| 2022 | $1,193 |
| 2021 | $600 |
| 2020 | $605 |
| 2019 | $482 |
| 2018 | $111 |
| 2017 | $107 |
| 2016 | $67 |
Ultragenyx Pharmaceutical Inc. Total Liabilities — FAQ
Ultragenyx Pharmaceutical Inc. (RARE) total liabilities over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see RARE's total liabilities history?
The chart and table above show Ultragenyx Pharmaceutical Inc.'s total liabilities by year and by quarter, including the growth rate.